Where Does Edwards Lifesciences (EW) Value Sit After TAVR Coverage Expansion?

Edwards Lifesciences has delivered a mixed share price story, with a long term decline sitting alongside shorter term gains. That raises a sharp question about what investors are really paying for in its cash flows today. With fresh policy support for its heart valve procedures now in place, the gap between the stock price and the cash it can generate has become an important issue for anyone looking at Edwards Lifesciences stock.

• Over the past 5 years, the share price declined 27.1%. This puts the focus squarely on whether the underlying cash generation justifies where the stock trades now.
• The recent move by the Centers for Medicare & Medicaid Services to widen Medicare access for transcatheter aortic valve replacement can influence expectations for future procedure volumes and the timing of Edwards Lifesciences' cash inflows.
• If you'd rather focus on earnings, this one's for you. See why Edwards Lifesciences's 51.9x P/E tells a different valuation story.

The stock's next move may depend on whether Edwards Lifesciences' current share price lines up with the intrinsic value suggested by its projected cash flows.

If you want to stress test this same cash flow question beyond Edwards Lifesciences, widen the lens to companies in the solid balance sheet and fundamentals stocks screener (23 results).

Is Edwards Lifesciences Fairly Priced on Cash Flow?

The Discounted Cash Flow (DCF) model here weighs what Edwards Lifesciences might earn for shareholders against the price you pay today. Latest twelve month free cash flow sits at about $1.40b, and the projections used in the model assume that this pool of cash continues to grow over time rather than shrink. Those estimates step up from the current level into the early 2030s, then ease into a slower second stage, which is typical for a business that is expected to mature rather than chase breakneck expansion indefinitely.

The DCF output places Edwards Lifesciences' estimated intrinsic value broadly in line with the current share price of $88.25, which implies the market already prices in a fair amount of future cash generation. Because the recent expansion of Medicare coverage for TAVR could support procedure volumes and future cash inflows, the lack of a clear discount in the model helps explain why the stock does not trade materially away from that intrinsic value range. Find out what Edwards Lifesciences could be worth using our Discounted Cash Flow (DCF) estimate.

The Edwards Lifesciences Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Edwards Lifesciences connect the valuation puzzle above to concrete expectations about the business. They spell out which paths for revenue growth, profitability and earnings would need to hold for the stock to be worth materially more or less than today. Instead of a single model output, they lay out the future that number rests on so you can watch real world results and see whether those assumptions still stack up.

One of the top community narratives on Edwards Lifesciences: 13% undervalued

"Bullish analysts describe Edwards Lifesciences as entering a new growth phase, with continued TAVR adoption and expansion into structural heart therapies..."

Discover why this Narrative puts Edwards Lifesciences at 13% undervalued.

One more Edwards Lifesciences question before you log off

The cash flow story is only part of Edwards Lifesciences, because the people making capital decisions and the way their pay is structured can tilt outcomes for shareholders in subtle but powerful ways. See who runs Edwards Lifesciences and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com